Curis is focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers with substantial unmet therapeutic/medical need.
CUDC-907 is an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. Curis is currently investigating CUDC-907 in two studies: a Phase 2 clinical trial in patients with relapsed, refractory diffuse large B-cell lymphoma, or DLBCL, and a Phase 1 trial in patients with solid tumors.
CA-170 is a first-in-class, orally-available, small molecule antagonist of the immune checkpoints PD-L1 and VISTA. CA-170 is currently undergoing investigation in a Phase 1 clinical trial in patients with advanced solid tumors and lymphoma.
CA-327 is a first-in-class, orally-available, small molecule antagonist of the immune checkpoints PD-L1 and TIM3. CA-327 is currently undergoing IND-enabling studies, and the company expects to file an IND and initiate clinical testing of CA-327 in 2017.
CA-4948, an orally-available, small molecule inhibitor of the IRAK4 kinase is currently undergoing IND-enabling studies, and the company expects to file an IND and initiate clinical testing of CA-4948 in 2017.
Erivedge® (vismodegib) was developed in collaboration with Genentech (a member of the Roche group) and is being commercialized by Genentech and Roche for the treatment of advanced basal cell carcinoma (BCC). Erivedge® is approved for use in patients with advanced BCC in the United States, European Union, and several other countries. Roche and Genentech are also continuing the development of Erivedge® in less severe forms of BCC as well as in other diseases such as idiopathic pulmonary fibrosis, or IPF, and myelofibrosis.
|© Curis, Inc. 2017 - All Rights Reserved|